CN114796288A - 一种用于烧烫伤的外用药及其制备方法 - Google Patents
一种用于烧烫伤的外用药及其制备方法 Download PDFInfo
- Publication number
- CN114796288A CN114796288A CN202210439275.XA CN202210439275A CN114796288A CN 114796288 A CN114796288 A CN 114796288A CN 202210439275 A CN202210439275 A CN 202210439275A CN 114796288 A CN114796288 A CN 114796288A
- Authority
- CN
- China
- Prior art keywords
- burns
- scalds
- parts
- medicine
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 206010053615 Thermal burn Diseases 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title abstract description 27
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 49
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 49
- 241000018646 Pinus brutia Species 0.000 claims abstract description 49
- 239000000843 powder Substances 0.000 claims abstract description 35
- 239000002994 raw material Substances 0.000 claims abstract description 27
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 20
- 241000402754 Erythranthe moschata Species 0.000 claims abstract description 17
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940116229 borneol Drugs 0.000 claims abstract description 15
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 7
- 230000001741 anti-phlogistic effect Effects 0.000 claims abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 241000972155 Moschus Species 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 229940124530 sulfonamide Drugs 0.000 claims description 9
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000005360 mashing Methods 0.000 claims description 8
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims description 7
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims description 7
- 229960004306 sulfadiazine Drugs 0.000 claims description 5
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 5
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 claims description 5
- 229960002229 sulfametoxydiazine Drugs 0.000 claims description 5
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 4
- 229960002135 sulfadimidine Drugs 0.000 claims description 3
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 claims description 3
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims 1
- 229960001907 nitrofurazone Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 37
- 208000002193 Pain Diseases 0.000 abstract description 23
- 230000008961 swelling Effects 0.000 abstract description 13
- 230000001737 promoting effect Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 231100000241 scar Toxicity 0.000 abstract description 6
- 208000032544 Cicatrix Diseases 0.000 abstract description 4
- 230000003467 diminishing effect Effects 0.000 abstract description 4
- 230000037387 scars Effects 0.000 abstract description 4
- 230000017423 tissue regeneration Effects 0.000 abstract description 4
- 230000029663 wound healing Effects 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 description 56
- 206010052428 Wound Diseases 0.000 description 54
- 241000894006 Bacteria Species 0.000 description 21
- 206010042674 Swelling Diseases 0.000 description 11
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000003179 granulation Effects 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 210000000416 exudates and transudate Anatomy 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 150000003456 sulfonamides Chemical class 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000002344 surface layer Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 3
- 229920001991 Proanthocyanidin Polymers 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000008728 vascular permeability Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- -1 hydroxy free radical Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 206010040860 Skin haemorrhages Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000186064 Trueperella pyogenes Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003546 nucleic acid damage Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N palmityl palmitate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/345—Nitrofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本申请提供一种用于烧烫伤的外用药及其制备方法,涉及外用药技术领域。一种用于烧烫伤的外用药,按重量份数计,包括以下原料:400‑700份松树提取物,10‑30份冰片,5‑15份消炎粉和1‑10份麝香。本申请的用于烧烫伤的外用药具有消炎止痛、消肿生肌之效,能够加快伤口愈合,减少疤痕产生。本申请的用于烧烫伤的外用药的制备方法,操作简单,便于生产,现配现用,实用性高。
Description
技术领域
本申请涉及外用药技术领域,具体而言,涉及一种用于烧烫伤的外用药及其制备方法。
背景技术
烧烫伤是一种常见的疾病,长久以来困扰着广大患者。烧烫伤是皮肤的热损伤,热毒为患,因此,如何保护创面、减少渗出、预防感染是需要解决的主要问题。
目前治疗烧烫伤用的药物品种较多,基本可分为中药和西药,都是在被烧伤后起泡、皮破、溃烂后的不及时被动治疗,给患者带来极大的痛苦,给家庭造成经济损失和担心劳累,甚至会造成残废和外观失美的巨大心理压力;另外,西药的原料多为化学物质,功效单一,又或对人皮肤会产生刺激,有的长期使用会有依赖性或有副作用。中医药在外治烧伤方面有丰富的经验,近年中医药外治烧伤的理论水平不断提高,临床经验不断丰富,临床优势越来越明显。
发明内容
本申请的目的在于提供一种用于烧烫伤的外用药,具有消炎止痛、消肿生肌之效,能够加快伤口愈合,减少疤痕产生。
本申请的另一目的在于提供一种用于烧烫伤的外用药的制备方法,操作简单,便于生产,现配现用,实用性高。
本申请解决其技术问题是采用以下技术方案来实现的。
本申请提出一种用于烧烫伤的外用药,按重量份数计,包括以下原料:400-700份松树提取物,10-30份冰片,5-10份消炎粉和3-5份麝香。
本申请提出一种用于烧烫伤的外用药的制备方法,包括以下步骤:
将消炎粉加入松树提取物中,加热混合,冷却,再加入冰片和麝香,搅拌。
本申请实施例至少具有以下有益效果:
本申请中,松树提取物、冰片、消炎粉和麝香配合使用,通过吸收创面渗出液,降低创面湿润程度,改善创面环境,达到止痛的目的;通过改变细菌细胞壁、细胞浆的渗透性,起到抑菌作用;通过在创面表面形成保护膜,避免创面被外界环境污染;通过促进药物中有效成分的吸收,使其快速穿过皮肤表层,直达病灶,更好地发挥消肿止痛、清热解毒之效;通过增加血管通透性,消除体内炎症;通过抑制细菌生长或杀灭细菌,减少细菌对创面的伤害,防止创面感染;通过生肌、生皮之效,促进创口肉芽生长,使创面重新生长;几方面协同作用,让创面愈合速度快,愈合效果好,减少疤痕产生,提高对烧烫伤的治疗效果。
本申请中,通过改变添加顺序,让原料的有效成分相辅相成,以达到清热解毒、消肿止痛、益气养阴之效,从而对创面进行修复,增强治疗效果。且制备方法操作简单,便于生产,现配现用,实用性高。
具体实施方式
为使本申请实施例的目的、技术方案和优点更加清楚,下面将对本申请实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
需要说明的是,在不冲突的情况下,本申请中的实施例及实施例中的特征可以相互组合。下面将参考具体实施例来详细说明本申请。
一种用于烧烫伤的外用药,按重量份数计,包括以下原料:400-700份松树提取物,10-30份冰片,5-10份消炎粉和3-5份麝香。
松树提取物,含有多酚类物质,主要活性成分是前花青素的低分子聚合体,含前花青素大于95%,前花青素是世界上所发现的作用最强的天然抗氧化剂,能去除体内自由基。松树提取物能延长维生素C在人体内的功效,激活维生素C和维生素E的作用,抑制脂蛋白氧化和羟自由基引起的核酸损伤,激活人体成长荷尔蒙的分泌,提高免疫反应和保护神经细胞免受由谷氨酸的盐、脂或其阴离子形式所引起的破坏,可以延缓衰老进程中出现的免疫力下降和血细胞新陈代谢功能衰退,并将它们恢复到正常水平。
松树提取物中含油脂、鞣质、纤维素、蛋白质等高分子结构,有较强的的吸水能力,能够将烧烫伤创面的水肿渗出液迅速吸出,改善创面的血液循环和缺氧状态,起到迅速止痛作用。其次,其吸收创面渗出液迅速形成的保护膜,保护创面减少体液渗出,保护创面不受外环境的污染。再者,其所含的高分子结构物质,形成不利于细菌生长的内环境,改变细菌细胞壁、细胞浆的渗透性,起到抑菌和杀虫作用。
冰片有开窍醒神、清热散毒、明目退翳、消肿止痛的功效。冰片别名:片脑、桔片、龙脑香、梅花冰片、羯布罗香、梅花脑、冰片脑、梅冰等,冰片可用于闭证神昏,目赤肿痛,喉痹口疮,疮疡肿痛,溃后不敛等。其与麝香配合,能够增强消肿止痛之效。冰片中含有天然的透皮促进剂,能使这些药物快速穿过皮肤表层,直达病灶,促进人体对药物的吸收,有利于其他药用成分的发挥。其还是一种能抗菌抗炎的中药材,能让人体毛细血管通透性增加,消除身体内的多种炎症,让人体疼痛反应放慢;是一种性质寒凉的中药材,能消肿止痛、清热去火。
消炎粉具有消炎、治疗跌打肿痛的作用,主要用于链球菌和葡萄球菌引起的外伤感染,如划伤、摔伤、以及青春痘导致的感染等。
麝香性辛、温、无毒、味苦,入心、脾、肝经,有开窍、辟秽、通络、散淤之功能,主治中风、痰厥、惊痫、中恶烦闷、心腹暴痛、跌打损伤、痈疽肿毒。本品通关透窍,上达肌肉,内入骨髓,可很快进入肌肉及骨髓,能充分发挥药性。麝香具有生肌、生皮功效,能够促使创口肉芽生长、皮肤再生,促使患者创面重新生长,加快创面愈合。
松树提取物、冰片、消炎粉和麝香配合使用,通过吸收创面渗出液,降低创面湿润程度,改善创面环境,达到止痛的目的;通过改变细菌细胞壁、细胞浆的渗透性,起到抑菌作用;通过在创面表面形成保护膜,避免创面被外界环境污染;通过促进药物中有效成分的吸收,使其快速穿过皮肤表层,直达病灶,更好地发挥消肿止痛、清热解毒之效;通过增加血管通透性,消除体内炎症;通过抑制细菌生长或杀灭细菌,减少细菌对创面的伤害;通过生肌、生皮之效,促进创口肉芽生长,使创面重新生长;几方面协同作用,让创面愈合速度快,愈合效果好,减少疤痕产生,提高对烧烫伤的治疗效果。
本实施例中,消炎粉包括呋喃西宁粉或磺胺类药粉。
呋喃西宁粉是消毒防腐药,治疗细菌引起的皮肤及黏膜的感染,是通过干扰细胞代谢中酶的活动而起到杀菌灭菌的作用。磺胺类药物具有抗菌作用,对大多数革兰氏阳性菌和革兰氏阴性菌均有抑制作用。对磺胺药高度敏感的病原菌有:链球菌、肺炎球菌、沙门氏菌、化脓棒状杆菌、大肠杆菌等;次敏感菌有:葡萄球菌、变形杆菌、巴氏杆菌、产气荚膜梭菌、肺炎杆菌、炭疽杆菌、绿脓杆菌、李氏杆菌、痢疾杆菌等。
磺胺类药物为广谱抑菌剂,在结构上类似对氨基苯甲酸(PABA),可与PABA竞争性作用于细菌体内的二叶酸合成酶,从而阻止PABA作为原料合成细菌所需要叶酸的过程,减少了具有代谢活性的四氢叶酸的量,而后者则是细菌合成嘌吟、胸腺嘧啶核苷和脱氧核糖核酸(DNA)的必需物质,因此抑制了细菌的生长繁殖。磺胺药的作用可被PABA及其衍生物(普鲁卡因、丁卡因)所拮抗,此外脓液以及组织的分解产物的存在也起拮抗作用,因其可提供细菌生长的必需物质。磺胺类药对某些放线菌、衣原体和某些原虫如球虫、阿米巴原虫、弓形虫也有较好的作用。磺胺类药在体外和体内的抑菌作用强度是一致的,对感染的最后治愈还有赖于机体的防御机能,通过阻止细菌的叶酸代谢而抑制其生长繁殖。
本实施例中,磺胺类药粉包括磺胺嘧啶、磺胺甲氧嘧啶和磺胺二甲嘧啶中的一种或多种。
磺胺嘧啶为治疗全身感染的中效磺胺,抗菌谱广,对大多数革兰氏阳性菌和阴性菌均有抑制作用,对脑膜炎双球菌、肺炎链球菌、淋球菌、溶血性链球菌的抑制作用较强,能通过血脑屏障渗入脑脊液。磺胺甲氧嘧啶主要用于防治溶血性链球菌、肺炎球菌及脑膜炎球菌引起的感染。磺胺二甲嘧啶主要用于敏感菌引起的轻症感染,如急性单纯性下尿路感染、急性中耳炎和皮肤软组织感染。
本实施例中,松树提取物的制备方法包括:取2-3月生长的松树尖,捣碎,过滤。
本实施例中,还包括按重量份数计的100-200份松脂。
松脂是由松类树干分泌出的树脂,在空气中呈粘滞液或块状固体,含松香和松节油。松香有燥湿杀虫、拔毒生肌、止痒止痛功能,用来治疗疖、痈、湿疹、脓疱疮及刀伤皮肤出血不止等症状。松脂主要由树脂酸和萜烃组成,能够在创面形成保护膜,避免创面受到外界环境污染,加快创面恢复。松脂、松树提取物和麝香配合,可以进一步增强消炎止痛、生肌润肤之效,进一步降低疤痕遗留,加快创面愈合。
一种用于烧烫伤的外用药的制备方法,包括以下步骤:
将消炎粉加入松树提取物中,再加入冰片和麝香,在80-90rpm搅拌5-10min。
通过改变添加顺序,让原料的有效成分相辅相成,以达到清热解毒、消肿止痛、益气养阴之效,从而对创面进行修复,增强治疗效果。且制备方法操作简单,便于生产,现配现用,实用性高。且在上述条件下,可以更好地让原料混合,同时不会让原料有效成分遗失或破坏。
以下结合实施例对本申请的特征和性能作进一步的详细描述。
实施例1
一种用于烧烫伤的外用药,包括以下原料:包括以下原料:500mL松树提取物,15g冰片,8g呋喃西宁粉和4g麝香。
一种用于烧烫伤的外用药的制备方法,包括以下步骤:
松树提取物的制备方法包括:取3月生长的松树尖,捣碎,过滤;
将呋喃西宁粉加入松树提取物中,再加入冰片和麝香,在90rpm搅拌8min,静置1h。
实施例2
一种用于烧烫伤的外用药,包括以下原料:包括以下原料:400mL松树提取物,10g冰片,5g呋喃西宁粉和3g麝香。
一种用于烧烫伤的外用药的制备方法,包括以下步骤:
松树提取物的制备方法包括:取2月生长的松树尖,捣碎,过滤;
将呋喃西宁粉加入松树提取物中,再加入冰片和麝香,在80rpm搅拌5min,静置1h。
实施例3
一种用于烧烫伤的外用药,包括以下原料:包括以下原料:700mL松树提取物,30g冰片,10g呋喃西宁粉和5g麝香。
一种用于烧烫伤的外用药的制备方法,包括以下步骤:
松树提取物的制备方法包括:取3月生长的松树尖,捣碎,过滤;
将呋喃西宁粉加入松树提取物中,再加入冰片和麝香,在90rpm搅拌10min,静置2h。
实施例4
一种用于烧烫伤的外用药,包括以下原料:包括以下原料:500mL松树提取物,15g冰片,8g呋喃西宁粉,4g麝香和120g松脂。
一种用于烧烫伤的外用药的制备方法,包括以下步骤:
松树提取物的制备方法包括:取3月生长的松树尖,捣碎,过滤;
将呋喃西宁粉加入松树提取物中,再加入冰片、麝香和松脂,在90rpm搅拌8min,静置1h。
实施例5
一种用于烧烫伤的外用药,包括以下原料:包括以下原料:500mL松树提取物,15g冰片,8g磺胺嘧啶和4g麝香。
一种用于烧烫伤的外用药的制备方法,包括以下步骤:
松树提取物的制备方法包括:取3月生长的松树尖,捣碎,过滤;
将磺胺嘧啶加入松树提取物中,再加入冰片和麝香,在90rpm搅拌8min,静置1h。
实施例6
一种用于烧烫伤的外用药,包括以下原料:包括以下原料:500mL松树提取物,15g冰片,8g磺胺甲氧嘧啶,4g麝香和120g松脂。
一种用于烧烫伤的外用药的制备方法,包括以下步骤:
松树提取物的制备方法包括:取3月生长的松树尖,捣碎,过滤;
将磺胺甲氧嘧啶加入松树提取物中,再加入冰片、麝香和松脂,在90rpm搅拌8min,静置1h。
对比例1
本对比例与实施例1不同的是:原料中不含松树提取物。
对比例2
本对比例与实施例1不同的是:原料中不含消炎粉。
对比例3
本实施例与实施例1原料相同,不同的是制备方法:直接将松树提取物、消炎粉、冰片和麝香混合。
试验结果
选择45例志愿者,烧烫伤程度为II°,烧伤部位以足背、小腿、大腿、手掌、手臂。随机分为9组,每组5人,对应使用实施例1-6和对比例1-3的药物。
使用方法:用消毒水洗净创面,剪去水泡或坏死组织,将药物涂抹在创面上,每日2-3次,连续使用10天,观察2、5、8、10天创面的变化情况,结果如下:
表1烧烫伤试验结果
根据表1可知,本发明实施例1-6的外用药能够减少创面渗出液,具有明显的消炎止痛之效。且根据实施例4与其余实施例比较可知,添加了松脂,外用药的起效速度更快,伤口愈合情况更好。对比例1-2与实施例1相比,消炎粉和松树提取物能够加快外用药对烧烫伤的治疗速度,快速减少创面渗出液,使得伤口恢复更快。当消炎粉与松树提取物配合使用时,通过明显减少渗出液,避免细菌感染,加强消炎止痛之效,进而让创口更快恢复,两者具有明显的协同增效作用。
对比例3与实施例1相比,原料的混合顺序或混合条件能够影响外用药的起效时间,在实施例1的制备条件下,外用药的起效速度更快,治愈速度更快,伤口恢复效果更好。实施例1、5、6相比,消炎粉选用呋喃西宁粉或磺胺类药粉,外用药的使用效果相差不大。实施例1-3相比,外用药中原料的不同比例会影响对伤口的治疗效果,在实施例1的配比下,外用药的起效速度最快,让伤口更快恢复。
综上所述,本申请实施例的用于烧烫伤的外用药,松树提取物、冰片、消炎粉和麝香配合使用,通过吸收创面渗出液,降低创面湿润程度,改善创面环境,达到止痛的目的;通过改变细菌细胞壁、细胞浆的渗透性,起到抑菌作用;通过在创面表面形成保护膜,避免创面被外界环境污染;通过促进药物中有效成分的吸收,使其快速穿过皮肤表层,直达病灶,更好地发挥消肿止痛、清热解毒之效;通过增加血管通透性,消除体内炎症;通过抑制细菌生长或杀灭细菌,减少细菌对创面的伤害;通过生肌、生皮之效,促进创口肉芽生长,使创面重新生长;几方面协同作用,让创面愈合速度快,愈合效果好,减少疤痕产生,提高对烧烫伤的治疗效果。
本申请实施例的用于烧烫伤的外用药的制备方法,通过改变添加顺序,让原料的有效成分相辅相成,以达到清热解毒、消肿止痛、益气养阴之效,从而对创面进行修复,增强治疗效果。且制备方法操作简单,便于生产,现配现用,实用性高。
以上所描述的实施例是本申请一部分实施例,而不是全部的实施例。本申请的实施例的详细描述并非旨在限制要求保护的本申请的范围,而是仅仅表示本申请的选定实施例。基于本申请中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本申请保护的范围。
Claims (7)
1.一种用于烧烫伤的外用药,其特征在于,按重量份数计,包括以下原料:400-700份松树提取物,10-30份冰片,5-10份消炎粉和3-5份麝香。
2.根据权利要求1所述的用于烧烫伤的外用药,其特征在于,所述消炎粉包括呋喃西宁粉或磺胺类药粉。
3.根据权利要求2所述的用于烧烫伤的外用药,其特征在于,所述磺胺类药粉包括磺胺嘧啶、磺胺甲氧嘧啶和磺胺二甲嘧啶中的一种或多种。
4.根据权利要求3所述的用于烧烫伤的外用药,其特征在于,所述松树提取物的制备方法包括:取2-3月生长的松树尖,捣碎,过滤。
5.根据权利要求4所述的用于烧烫伤的外用药,其特征在于,还包括按重量份数计的100-200份松脂。
6.一种如权利要求1-5任一项所述的用于烧烫伤的外用药的制备方法,其特征在于,包括以下步骤:将消炎粉加入松树提取物中,再加入冰片和麝香,搅拌。
7.根据权利要求6所述的制备方法,其特征在于,搅拌时,在80-90rpm搅拌5-10min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210439275.XA CN114796288A (zh) | 2022-04-25 | 2022-04-25 | 一种用于烧烫伤的外用药及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210439275.XA CN114796288A (zh) | 2022-04-25 | 2022-04-25 | 一种用于烧烫伤的外用药及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114796288A true CN114796288A (zh) | 2022-07-29 |
Family
ID=82507634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210439275.XA Pending CN114796288A (zh) | 2022-04-25 | 2022-04-25 | 一种用于烧烫伤的外用药及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114796288A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1327829A (zh) * | 2001-06-07 | 2001-12-26 | 黄宝生 | 烫创伤茶叶籽油药膏及制作方法 |
CN1371693A (zh) * | 2001-02-20 | 2002-10-02 | 孙世君 | 一种治疗烫烧伤等皮肤创伤的药物 |
CN1911231A (zh) * | 2006-08-18 | 2007-02-14 | 李伟华 | 一种烧伤药物 |
CN101385781A (zh) * | 2008-10-28 | 2009-03-18 | 刘廷洲 | 一种治疗烧烫伤的中药 |
CN103705549A (zh) * | 2013-12-15 | 2014-04-09 | 盛光辉 | 一种烫伤用颗粒剂的制备方法 |
CN111920824A (zh) * | 2020-09-11 | 2020-11-13 | 余朝权 | 一种治疗伤口的中药组合物 |
-
2022
- 2022-04-25 CN CN202210439275.XA patent/CN114796288A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1371693A (zh) * | 2001-02-20 | 2002-10-02 | 孙世君 | 一种治疗烫烧伤等皮肤创伤的药物 |
CN1327829A (zh) * | 2001-06-07 | 2001-12-26 | 黄宝生 | 烫创伤茶叶籽油药膏及制作方法 |
CN1911231A (zh) * | 2006-08-18 | 2007-02-14 | 李伟华 | 一种烧伤药物 |
CN101385781A (zh) * | 2008-10-28 | 2009-03-18 | 刘廷洲 | 一种治疗烧烫伤的中药 |
CN103705549A (zh) * | 2013-12-15 | 2014-04-09 | 盛光辉 | 一种烫伤用颗粒剂的制备方法 |
CN111920824A (zh) * | 2020-09-11 | 2020-11-13 | 余朝权 | 一种治疗伤口的中药组合物 |
Non-Patent Citations (4)
Title |
---|
张琦: "呋喃西林治疗烧烫伤300例观察" * |
汪三姓: "麝香生肌散促进皮肤创面愈合的临床研究" * |
程东海: "烧伤药纱临床应用研究" * |
胡辅庆: "松树皮粉治疗Ⅱ°以上烧烫伤50例" * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014190179A2 (en) | Urea silicon gel for scars and hydration treatment and method of using same | |
US20140348873A1 (en) | Urea-Silicone Gel for Hyperkeratosis Treatment | |
RU2325175C2 (ru) | Мазь для лечения ожогов, кожных заболеваний и заживления ран | |
US7790928B1 (en) | Therapeutic dimethyl sulfoxide (aka DMSO) compositions and methods of use | |
US20230390176A1 (en) | Cosmetic Skin and Medical Cream | |
CN106880765B (zh) | 一种促进伤口愈合的粉剂 | |
CN114796288A (zh) | 一种用于烧烫伤的外用药及其制备方法 | |
RU2416425C1 (ru) | Масло противопролежневое | |
US20080193552A1 (en) | Topical medicament for skin injuries and disorders | |
EP3313369B1 (en) | Emollient composition | |
US5616619A (en) | Topical composition for burn relief and method of use | |
Mahmood et al. | Evaluation of in vivo wound healing activity of Chromolaena odorata leaf extract on excision wounds model in rats | |
US9968703B1 (en) | Burn wound composition and methods for treating burn wounds | |
US8173183B2 (en) | Mucosal membrane healant and moisturizer | |
CN110624032A (zh) | 一种治疗烧烫伤的膏剂及其制备方法 | |
US5576005A (en) | Effectiveness of wart removal by compositions including propolis | |
RU2086233C1 (ru) | Мазь для лечения гнойно-воспалительных процессов | |
MX2013004077A (es) | Composicion farmaceutica a base de centella asiatica (hydrocotyle asiatica l.) para el tratamiento de ulceras en miembros inferiores. | |
WO1998043613A1 (fr) | Onguents pour traiter tous les stades de lesions suppuratives, brulures et ulcers trophiques, modes de preparation et applications | |
RU2139708C1 (ru) | Мазь "звар" для лечения гнойных и инфицированных ран различной этиологии | |
RU2355411C1 (ru) | Ранозаживляющая мазь | |
RU2256441C1 (ru) | Мазь для лечения ожогов, гнойных и инфицированных ран различной этиологии и способ лечения ожогов, гнойных и инфицированных ран | |
Pegg | The role of drugs in management of burns | |
KR100289906B1 (ko) | 피부용조성물 | |
AU687840B2 (en) | Topical composition for burn relief and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220729 |